
Opinion|Videos|September 20, 2024
Future Directions in mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
Advertisement
Episodes in this series

- How do you see the treatment landscape for mCRPC evolving in the coming years?
- What advice would you offer community oncologists for staying up to date with the rapidly changing field of mCRPC management?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5

















